Stock Update: Amgen Inc (NASDAQ:AMGN) – FDA Accepts Amgen’s Biologics License Application For LDL Cholesterol-Lowering Medication Evolocumab

[PR Newswire] – THOUSAND OAKS, Calif., Nov. 10, 2014 /PRNewswire/ — Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review Amgen’s Biologics License Application … . . . → Read More: Stock Update: Amgen Inc (NASDAQ:AMGN) – FDA Accepts Amgen’s Biologics License Application For LDL Cholesterol-Lowering Medication Evolocumab Similar Articles: Stock Update: Amgen Inc (NASDAQ:AMGN) – Amgen ovarian cancer drug fails to improve overall survival Company Update: Amgen Inc (NASDAQ:AMGN) – Amgen submits U.S. application to sell cholesterol-fighting drug Company Update (NYSE:DUK): Duke Energy files Keowee-Toxaway license application